deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT01055106

Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

A Multicenter, Randomized, Investigator-Blinded, Phase 2, Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

Sponsor: Graceway Pharmaceuticals, LLC

Conditions Vaginal Infection Vaginosis, Bacterial
Interventions GW05 Metronidazole
Updated 7 times since 2017 Last updated: Jun 28, 2011 Started: Jan 31, 2010 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Vaginal Infection and Vaginosis, Bacterial and is currently completed. Graceway Pharmaceuticals, LLC leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Graceway Pharmaceuticals, LLC
Data source: Graceway Pharmaceuticals, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Champaign, United States , Denver, United States , Grand Rapids, United States , Haverhill, United States , Houston, United States , Jackson, United States , Jonesboro, United States , Memphis, United States , Miami, United States and 9 more locations